From 11:00 pm to 12:00 pm EST ( 8:00 pm to 9:00 pm PST ) on January 6th, the website will be under maintenance. We are sorry for the inconvenience. Please arrange your schedule properly.
Epirubicin hydrochloride (4'-Epidoxorubicin hydrochloride), a semisynthetic L-arabino derivative of doxorubicin, has an antineoplastic agent by inhibiting Topoisomerase . Epirubicin hydrochloride inhibits DNA and RNA synthesis. Epirubicin hydrochloride is a Forkhead box protein p3 (Foxp3) inhibitor and inhibits regulatoryTcell activity .
ODN 1018 (1018 ISS) is a TLR9 agonist and immune modulator. ODN 1018 exhibits adjuvant activity and augments CD8+ T cell responses with LNP-encapsulated OVA peptides. ODN 1018 triggers sustained suppression of allergic airway inflammation. ODN 1018 can be used for the research of allergic asthma and systemic lupus erythematosus .
Isoallolithocholic acid (3β-Hydroxy-5α-cholanic acid), a derivative of Lithocholic acid (HY-10219), is a Tcellregulator. Isoallolithocholic acid enhances regulatoryTcells (Tregs) differentiation .
Lactose is a β-galactoside consisting of galactose and glucose residues, the main carbohydrate in mammalian breast milk. Lactose, a macronutrient and an inducer of host innate immune responses, possesses immune modulatory functions .
Zelasudil (RXC007) is an orally active, highly selective small molecule Rho-associated coiled-coil containing protein kinase 2 (ROCK2) inhibitor with anti-fibrotic efficacy. Zelasudil elicits positive immunomodulatory effects in metastatic pancreatic tumors with increase of CD8+ and CD4+ Tcell infiltrate into the tumor cortex and reduction in immunosuppressive FOXP3+ regulatoryTcells at the tumor border. Zelasudil is promising for research of pancreatic ductal adenocarcinoma .
Epirubicin (4'-Epidoxorubicin), a semisynthetic L-arabino derivative of doxorubicin, has an antineoplastic agent by inhibiting Topoisomerase . Epirubicin inhibits DNA and RNA synthesis. Epirubicin is a Forkhead box protein p3 (Foxp3) inhibitor and inhibits regulatoryTcell activity .
Tivumecirnon (FLX475) is an orally active, selective CCR4 antagonist. Tivumecirnon blocks the binding of CCR4 to its ligands, CCL17 and CCL22, thereby reducing Treg infiltration into the tumor microenvironment. Tivumecirnon has antitumor activity .
Alemtuzumab (Campath-IH) is a humanized monoclonal antibody against CD52. Alemtuzumab does not cross-react with murine CD52. Alemtuzumab selectively targets the CD52 antigen to induce profound lymphocyte depletion, followed by recovery of T and B cells with regulatory phenotypes. Alemtuzumab is capable of complement-dependent cytotoxicity and antibody-dependent cell-mediated cytotoxicity (ADCC), as well as induction of apoptosis. Alemtuzumab has the potential for B-cell chronic lymphocytic leukaemia research .
Anti-Mouse CTLA-4 Antibody (9D9) is an anti-mouse CTLA-4 IgG2b monoclonal antibody. Anti-Mouse CTLA-4 Antibody (9D9) can bind to CTLA-4 and block its binding to B7. Anti-Mouse CTLA-4 Antibody (9D9) enhances Tcell function by increasing the ratio of CD8 +Tcells to regulatoryTcells (Tregs). Anti-Mouse CTLA-4 Antibody (9D9) can be used for research on cancer such as colon cancer and melanoma .
ODN 2216 is a type A CpG oligodeoxynucleotide vaccine adjuvant and a TLR9 agonist. ODN 2216 interacts with TLR9 in the lysosomes of CD4 +Tcells and activates feedback-dependent signaling pathways. ODN 2216 induces the production of type I interferons, IL-6 and TGF-β via the IRAK4/IRF7 axis, while increasing intracellular ATP levels. ODN 2216 not only induces the differentiation of CD4 +Tcells into anti-inflammatory Th3-like regulatory phenotypes to inhibit autologous proliferation, but also enhances the specific CD8 +Tcell-mediated cytotoxicity against Mammaglobin-A in breast cancer cells. ODN 2216 is widely used in studies related to breast cancer and systemic lupus erythematosus .
AS2863619 enables conversion of antigen-specific effector/memory Tcells into Foxp3 +regulatoryT (Treg) cells for the treatment of various immunological diseases. AS2863619 is a potent, orally active cyclin-dependent kinase 8 (CDK8) and CDK19 inhibitor with IC50s of 0.61 nM and 4.28 nM, respectively. STAT5 activation enhanced by AS2863619 inhibition of CDK8/19, which consequently activates the Foxp3 gene .
Ficerafusp alfa (BCA-101) is a bispecific antibody targeting EGFR and TGFβ, with a Kd of 2.58 nM against EGFR and a Kd of 61.3 nM against TGFβ1. Ficerafusp alfa binds to EGFR, inhibits EGFR phosphorylation, blocks EGF-dependent cell proliferation, and mediates antibody-dependent cellular cytotoxicity against EGFR-positive tumor cells. Ficerafusp alfa sequesters TGFβ via its TGFβRII ECD domain, neutralizes the activity of TGFβ and TGFβ1, and blocks TGFβ-dependent processes, including epithelial-mesenchymal transition, cell invasion, and differentiation of inducible regulatoryTcells. Ficerafusp alfa is applicable to research related to head and neck squamous cell carcinoma, advanced solid tumors, squamous non-small cell lung cancer, anal squamous cell carcinoma, colorectal cancer, and pancreatic cancer .
Siplizumab (MEDI-507) is a humanized IgG1 monoclonal antibody against CD2. Siplizumab depletes Tcells, decreases Tcell activation, inhibites Tcell proliferation and enriches naïve and bona fideregulatoryTcells .
(-)-Camphoric acid is the less active enantiomer of Camphoric acid. Camphoric acid induces glutamate receptor expression. Camphoric acid also significantly induces the activation of NF-κB and AP-1. Camphoric acid significantly stimulates the differentiation of mouse osteoblastic MC3T3-E1 subclone 4 cells. Camphoric acid has weak regulatory function towards glutamate receptors. Camphoric acid can induce mRNA expression of glutamate signaling molecules and activate transcription factors, thereby stimulating osteoblast differentiation .
Ligelizumab (QGE 031) is a humanized high-affinity anti-immunoglobulin IgE monoclonal antibody. Ligelizumab selectively inhibits the binding of IgE to the high-affinity receptor FcεRI, while the inhibitory effect on the low-affinity receptor CD23 is weak. Ligelizumab can inhibit the activation of effector cells such as mast cells and Basophil, while reducing the production of IgE by B cells, and restoring the IFN-α production and regulatoryTcell (Treg) induction function of plasmacytoid dendritic cells (pDC). Ligelizumab can be used in the study of allergic diseases (such as chronic spontaneous urticaria, allergic asthma) .
Melredableukin alfa (RG7835) is a bivalent conjugate composed of a human IL-2 mutant (T3A, N88D, C125A) and human IgG1. Melredableukin alfa exhibits enhanced Treg cell selectivity in cynomolgus monkey and humanized mouse models. Melredableukin alfa can be used in research related to ulcerative colitis and autoimmune hepatitis .
Tosposertib (TU2218 free base) is an ALK5/VEGFR2 dual inhibitor (IC50 = 1.2 nM/4.9 nM). Tosposertib directly restores the activity of damaged cytotoxic T lymphocytes (CTLs) and natural killer cells inhibited by TGFβ and suppresses the activity and viability of regulatoryTcells. Tosposertib can be used for the study of melanoma and colon cancer .
Daclizumab (Ro 24-7375) is a humanized, monoclonal antibody that blocks CD25 (α-subunit of the high-affinity interleukin-2 receptor (IL-2R-HA)). Daclizumab inhibits effector Tcell activation, regulatoryTcell (Treg) expansion and survival, and activation-induced T-cellapoptosis. Daclizumab increases IL-2 bioavailability to bind to the intermediate-affinity IL-2R (IL-2R-IA), driving the expansion of anti-inflammatory CD56bright natural killer (NK) cells. Daclizumab can be used for multiple sclerosis and cancer research .
PPACK TFA is an orally active, selective molecular glue degrader targeting IKZF2. Through a molecular glue mechanism, PPACK TFA binds to CRBN, recruits IKZF2 to form a ternary complex, and promotes its ubiquitination and proteasomal degradation. This further converts inhibitory regulatoryTcells (Treg) into effector-like Tcells, enhances CD8 +Tcell responses, and modulates the Teff:Treg balance. PPACK TFA also increases the production of the inflammatory cytokine IL-2 and reduces the suppressive activity of Treg. PPACK TFA can be used in cancer immunotherapy research, and exhibits a synergistic effect when combined with immune checkpoint inhibitors such as anti-PD1 .
ODN 2216 sodium is a type A CpG oligodeoxynucleotide vaccine adjuvant and a TLR9 agonist. ODN 2216 sodium interacts with TLR9 in the lysosomes of CD4 +Tcells and activates feedback-dependent signaling pathways. ODN 2216 sodium induces the production of type I interferons, IL-6 and TGF-β via the IRAK4/IRF7 axis, while increasing intracellular ATP levels. ODN 2216 sodium not only induces the differentiation of CD4 +Tcells into anti-inflammatory Th3-like regulatory phenotypes to inhibit autologous proliferation, but also enhances the specific CD8 +Tcell-mediated cytotoxicity against Mammaglobin-A in breast cancer cells. ODN 2216 sodium is widely used in studies related to breast cancer and systemic lupus erythematosus .
Gotistobart (ONC-392; BNT 316) is a humanized anti-CTLA-4 antibody with selective regulatoryTcell depletion activity in the tumor microenvironment. Gotistobart can be used for the research of cancer, such as non-small cell lung cancer .
BMS-986449 is a potent and orally active CELMoD molecular glue and an IKZF2/IKZF4 degrader. BMS-986449 targets the degradation of transcription factors Helios (IKZF2) and Eos (IKZF4) in regulatoryT (Treg) cells. BMS-986449 redirects the E3 ubiquitin ligase Cereblon to induce the degradation of Helios and Eos, reprogramming Treg cells and enhancing antitumor immunity. BMS-986449 is promising for research of advanced solid tumors .
GFH018 is an orally active, selective and ATP-competitive TGF-βR1 inhibitor with an IC50 of 40 nM. GFH018 reactivates the immune system by blocking the immunosuppression mediated by regulatoryTcells and M2 macrophages. GFH018 inhibits tumor angiogenesis. GFH018 suppresses tumor growth in mouse tumor models. GFH018 can be used for the research of solid tumors, hepatocellular carcinoma, colorectal cancer, breast cancer, and relapsed/metastatic nasopharyngeal carcinoma .
Ivuxolimab is a fully human IgG2 agonist targeting OX40 (CD134), which selectively binds to the OX40 receptor on the surface of activated CD4 + and CD8 +Tcells without inducing antibody-dependent cytotoxicity. Ivuxolimab can promote Tcell proliferation, survival and cytokine (such as IFN-γ, IL-2) secretion, inhibit regulatoryTcell function, and enhance anti-tumor immune response. Ivuxolimab can be used in the study of melanoma, hepatocellular carcinoma, head and neck squamous cell carcinoma, etc .
ALV1 is a molecular glue degrader for Ikaros (IKZF1) and Helios (IKZF2) with DC50 of 2.5 nM and 10.3 nM respectively. ALV1 bind CRBN with an IC50 of 0.55 μM, and induces CRBN-Helios dimerization. ALV1 can be used to study the properties and functions of regulatoryTcells .
Efavaleukin alfa (AMG592) is a IL-2 mutein fragment crystallizable fusion protein. Efavaleukin alfa drives the selective expansion of regulatoryTcells. Efavaleukin alfa is applicable to research related to systemic lupus erythematosus .
Tagmokitug (CHS-114; SRF-114) is a fully human IgG1 antibody targeting CCR8. Tagmokitug selectively binds to human CCR8 (Kd = 502 pM) and mediates the death of CCR8-expressing cells via antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis. Tagmokitug selectively eliminates intratumoral regulatoryTcells, induces tumor growth inhibition, remodels the tumor immune microenvironment, and promotes the differentiation of cytotoxic CD8 +Tcell subsets. Tagmokitug can be used for the research of solid tumors .
Peptide P60 is a FOXP3 inhibitor. Peptide P60 reduces the nuclear translocation of FOXP3 and impairs FOXP3-mediated inhibition of NF-κB and NFAT activity. Peptide P60 inhibits the immunosuppressive activity of regulatoryTcells and restores the proliferation and activation of effector Tcells. Peptide P60 induces lymphoproliferative autoimmune syndrome in neonatal ICR mice and reduces the number of CD4 +CD25 +Foxp3 +Tcells in the spleen. Peptide P60 enhances the efficacy of AH1 (HY-P4193) peptide vaccine and recombinant adenovirus-based HCV NS3 vaccine in BALB/c mice, including protective effects against CT26 tumor implantation. Peptide P60 can be used in studies related to tumor immunity, viral infection and lymphoproliferative autoimmune syndrome .
MK-1966 is an anti-IL-10 antibody. MK-1966 inhibits secretion of cytokines from activated macrophages, production of CC and CXC chemokines, and a TH1 response, down-regulates MHC and costimulatory molecules on dendritic cells (DCs), and induces regulatoryTcells. MK-1966 can be used for the research of cancer , such as gastric cancer .
Anti-Mouse CTLA-4/CD152 (LALA-PG) Antibody (9D9) is a mouse-derived IgG2a κ type antibody inhibitor targeting to mouse CTLA-4/CD152. Anti-Mouse CTLA-4/CD152 (LALA-PG) Antibody (9D9) contains a LALA-PG mutation in the Fc fragment rendering it unable to bind to endogenous Fcγ receptors. Anti-Mouse CTLA-4/CD152 (LALA-PG) Antibody (9D9) can be used for the researches of cancer and immunology, such as colon .
(±)-ML 209 (compound 4n), a diphenylpropanamide, is a retinoic acid-related orphan receptor RORγ antagonist with an IC50 of 1.1 μM. (±)-ML 209 inhibits RORγt transcriptional activity with an IC50 of 300 nM in HEK293tcells. (±)-ML 209 inhibits the transcriptional activity of RORγt, but not RORα in cells. (±)-ML 209 selectively inhibits murine Th17 cell differentiation without affecting the differentiation of naïve CD4 +Tcells into other lineages, including Th1 and regulatoryTcells .
Cergutuzumab is a fully human IgG1 antibody that targets carcinoembryonic antigen (CEA, CEACAM5, CD66e). Cergutuzumab can be used to form the recombinant protein Cergutuzumab amunaleukin (HY-P99498) .
PPACK dihydrochloride is an orally active, selective molecular glue degrader targeting IKZF2. Through a molecular glue mechanism, PPACK dihydrochloride binds to CRBN, recruits IKZF2 to form a ternary complex, and promotes its ubiquitination and proteasomal degradation. This further converts inhibitory regulatoryTcells (Treg) into effector-like Tcells, enhances CD8 +Tcell responses, and modulates the Teff:Treg balance. PPACK dihydrochloride also increases the production of the inflammatory cytokine IL-2 and reduces the suppressive activity of Treg. PPACK dihydrochloride can be used in cancer immunotherapy research, and exhibits a synergistic effect when combined with immune checkpoint inhibitors such as anti-PD1 .
PLX-4545 is an orally active, selective molecular glue degrader targeting IKZF2. Through a molecular glue mechanism, PLX-4545 binds to CRBN, recruits IKZF2 to form a ternary complex, and promotes its ubiquitination and proteasomal degradation. This further converts inhibitory regulatoryTcells (Treg) into effector-like Tcells, enhances CD8 +Tcell responses, and modulates the Teff:Treg balance. PLX-4545 also increases the production of the inflammatory cytokine IL-2 and reduces the suppressive activity of Treg. PLX-4545 can be used in cancer immunotherapy research, and exhibits a synergistic effect when combined with immune checkpoint inhibitors such as anti-PD1 .
AS2863619 free base enables conversion of antigen-specific effector/memory Tcells into Foxp3 +regulatoryT (Treg) cells for the treatment of various immunological diseases. AS2863619 free base is a potent, orally active cyclin-dependent kinase 8 (CDK8) and CDK19 inhibitor with IC50s of 0.61 nM and 4.28 nM, respectively. STAT5 activation enhanced by AS2863619 free base inhibition of CDK8/19, which consequently activates the Foxp3 gene .
(R)-BMS-986449 is the racemic mixture of BMS-986449 (HY-173630). BMS-986449 is a CELMoD molecular glue and an IKZF2/IKZF4 degrader. BMS-986449 targets the degradation of transcription factors Helios (IKZF2) and Eos (IKZF4) in regulatoryT (Treg) cells. BMS-986449 redirects the E3 ubiquitin ligase Cereblon to induce the degradation of Helios and Eos, reprogramming Treg cells and enhancing antitumor immunity. BMS-986449 is promising for research of advanced solid tumors .
AZD8701 (IONIS-1063734) is an antisense oligonucleotide targeting FOXP3 in regulatoryTcells (Tregs), with a human IC50 of 65.2 nM. AZD8701 binds to intronic sites of all FOXP3 pre-mRNA isoforms and mediates dose-dependent FOXP3 knockdown via free uptake. AZD8701 can be used in cancer-related research .
Ragifilimab (INCAGN-1876) is an agonist monoclonal antibody targeting the glucocorticoid-induced TNFR-related protein (GITR). Ragifilimab binds to and activates GITR on T cells, which stimulates the immune system to enhance its anti-tumor activity. Ragifilimab can be used for advanced or metastatic solid tumors research .
Quavonlimab (MK-1308) is a humanized IgG1 monoclonal antibody targeting CTLA-4. As a competitive inhibitor of CTLA-4, Quavonlimab blocks the binding of CTLA-4 to its ligands CD80 and CD86. Quavonlimab increases interferon production, expands and activates Tcells, reduces tumor regulatoryTcells, inhibits tumor growth, and induces the proliferation of Ki67-positive CD4 and CD8 cells. Quavonlimab can be used in studies related to solid tumors .
(1S,2S,3R)-PLX-4545 is the (1S,2S,3R) enantiomer of PLX-4545 (HY-159647). PLX-4545 is an orally active and selective cereblon-based molecular glue degrader of IKZF2 (zinc finger transcription factor Helios). PLX-4545 can reprogram immunosuppressive regulatoryTcells into pro-inflammatory effector Tcells, thereby enhancing anti-tumor immune responses .
KLF10-IN-1 (#48-15) is a KLF10 inhibitor with an IC50 value of 40 μM for KLF10 reporter gene. KLF10-IN-1 can inhibit KLF10-DNA binding and transcriptional activity, block the conversion of CD4+CD25 Tcells to CD4+CD25+Tregulatorycells, and inhibit the expression of KLF10 target genes. KLF10-IN-1 can be used as a useful mechanistic probe to study KLF10-mediated effects and Tregulatorycell biology .
FTI-277 is a farnesyltransferase (FTase) inhibitor. FTI-277 inhibits Ras farnesylation, blocks the phosphorylation of downstream ERK1/2 and mTOR, and reduces membrane-bound active N-ras protein. FTI-277 activates caspase 3, upregulates Bim expression, induces cellapoptosis, suppresses regulatoryTcell expansion, enhances macrophage phagocytosis, and improves bacterial clearance. FTI-277 activates the PI3K/Akt signaling pathway, inhibits osteoblast differentiation, and reduces the proliferation ability of neuroblastoma cells. FTI-277 can be used in research related to head and neck squamous cell carcinoma, neuroblastoma, sepsis, and vascular calcification .
Isoallolithocholic acid-d2 is the deuterium labeled Isoallolithocholic acid (HY-B0172A). Isoallolithocholic acid is a Tcellregulator and enhances regulatoryTcells (Tregs) differentiation .
Revdofilimab (ABBV-368) is a human IgG1 agonist monoclonal antibody against OX40. Among them, OX40 is a member of the TNF receptor superfamily expressed on activated and memory Tcell subsets and Tregulatorycells .
NDI-101150 is an orally active, potent and selective hematopoietic progenitor cell kinase 1 (HPK1) inhibitor with an IC50 of 0.7 nM. NDI-101150 blocks HPK1-mediated negative regulation of immune receptor signaling, inhibits immunosuppression of T cell activation, enhances antigen-specific antibody production and augments B-cell activation. NDI-101150 inhibits tumor growth in syngeneic tumor models, establishes durable antitumor immune memory, and synergizes with anti-PD1 to enhance exhausted T cell activity and drive tumor regressions. NDI-101150 can be used for the research of cancer, such as breast cancer and colon cancer .
PQA-18 is a unique PAK2 inhibitor (IC50: 10 nM). PQA-18 has immunosuppressing effects. PQA-18 suppresses IL2, IL4, IL6, and TNFα. PQA-18 inhibits the population of a subset of regulatoryTcells and the immunoglobulin (Ig) production against Tcell-dependent antigens as well as alleviates dermatitis in mice .
4A-MPLA ammonium is an orally active TLR4 agonist. 4A-MPLA ammonium induces TLR4 endocytosis dependent on Cdc42 and galectin-3, triggering TRIF-mediated signaling and sustained IFN-β production. 4A-MPLA ammonium promotes lipid droplet formation, upregulates interferon-stimulated genes and type I IFN signaling genes, downregulates lysosome/phagosome function genes, and modulates tolerogenic dendritic cell function. 4A-MPLA ammonium can be used for the research of colitis .
SR1555 is a specific retinoic acid receptor-related orphan nuclear receptor γ (RORγ) inverse agonist with an IC50 value of 1 μM. SR1555 not only inhibits TH17 cell development and function but also increases the frequency of Tregulatorycells, as well as inhibits the expression of IL-17. SR1555 can be used for researching autoimmune diseases .
Resolvin D5 is an anti-inflammatory and analgesic agent produced in M2 macrophages. Resolvin D5 alleviates Paclitaxel (HY-B0015)-induced mechanical allodynia and inflammatory pain by activating the GPR32 receptor, with gender specificity (effective only in male mice) and independence from TRPV1 or TRPA1 channels. Resolvin D5 attenuates LPS-induced ERK phosphorylation and NF-κB nuclear translocation, downregulates proinflammatory mediators such as IL-6 and CCL5, inhibits Th17 cell differentiation and osteoclastogenesis, promotes regulatoryTcell differentiation, and shows no cytotoxicity to human monocytes. The level of Resolvin D5 is elevated in arthritic SKG mice, but Resolvin D5 has no effect on dendritic cell differentiation or M1 macrophage polarization, nor does it prevent ZyA-induced arthritis progression. Resolvin D5 is suitable for research related to chemotherapy-induced peripheral neuropathy, inflammatory pain and rheumatoid arthritis .
BMS-986156 is a fully humanized IgG1 agonist monoclonal antibody agonist corticosteroid-induced tumor necrosis factor receptor-related protein (GITR). BMS-986156 binds to GITR and promotes activation of T effector cells and inactivates Tregulatorycells. BMS-986156 is indicated for use in advanced solid tumor studies .
Ieramilimab (LAG525; IMP701) is a humanized IgG4 monoclonal antibody that binds to LAG-3, resulting in inhibition of LAG-3 interaction with MHC-II molecules. Ieramilimab restores T-cell and NK-cell-mediated antileukemic immunity by reducing exhaustion and augmenting cytokine output and cytotoxicity. Ieramilimab increases the infiltration of cytotoxic T lymphocytes and reduces baseline densities of regulatoryTcells (Tregs) and ADAM10-expressing tumor cells. Ieramilimab can be used for the study of various malignancies including melanoma, RCC, and advanced solid tumors .
PTX-35 is a human IgG monoclonal antibody (mAb) targeting TNFRSF25. PTX-35 reduces the suppressive activity of regulatoryTcells and enhances CD4+ Tcell effector responses in a mouse melanoma model. PTX-35 can be used in Islet cell transplant rejection and Solid tumours research. Recommended isotype control: Human IgG1 lambda2, Isotype Control (HY-P990096) .
Epirubicin (hydrochloride) (Standard) is the analytical standard of Epirubicin (hydrochloride). This product is intended for research and analytical applications. Epirubicin hydrochloride (4'-Epidoxorubicin hydrochloride), a semisynthetic L-arabino derivative of doxorubicin, has an antineoplastic agent by inhibiting Topoisomerase . Epirubicin hydrochloride inhibits DNA and RNA synthesis. Epirubicin hydrochloride is a Forkhead box protein p3 (Foxp3) inhibitor and inhibits regulatoryTcell activity .
Imneskibart (AU-007) is a human monoclonal antibody that binds to the CD25-binding epitope of interleukin-2 (IL-2), blocking the binding of IL-2 to the trimeric IL-2 receptor while retaining the ability to bind to the dimeric IL-2 receptor. Imneskibart expands effector Tcell and NK cell populations, reduces regulatoryTcells, increases the effector Tcell/regulatoryTcell ratio, and alleviates vascular leakage. Imneskibart can be used in research related to melanoma and non-small cell lung cancer. The corresponding isotype control is: Human IgG1 kappa, Isotype Control (HY-P99001) .
4-Octylphenol is a hormone disruptor that has gender-specific effects on male reproductive cells, significantly reducing the mitotic index and the number of spermatogonia. 4-Octylphenol can cause inflammatory damage to fish gills by activating the complement system through the C3a/C3aR axis and the C5a/C5aR1 axis, this leads to complement activation and causes immune suppression due to the imbalance between Th1/Th2 cells and regulatoryTcells (Treg)/Th17 cells, as well as inflammatory damage via the Toll-like receptor 7 (Toll-like Receptor (TLR))/IκBα/NF-κB pathway .
Porustobart (HBM-4003) is a fully human anti-CTLA-4 heavy chain only antibody (HCAb). Porustobart can significantly improve the depletion of regulatoryTcells (Treg cells) with high CTLA-4 expression in tumor tissues by enhancing ADCC activity. Porustobart can be used for tumor research .
BI-5756 is a CETP inhibitor and cannabinoid receptor 1 (CB1) agonist. BI-5756 can significantly increase HDL-C levels and reduce LDL-C levels. BI-5756 can also enhance the function of regulatoryTcells while maintaining Tcell-mediated anti-tumor activity. BI-5756 can directly inhibit the growth of tumor cells and upregulate the expression of MHC I, MHC II, and CD80 on tumor cells. BI-5756 has a protective effect in graft-versus-host disease models. BI-5756 can be used in research on tumors, graft-versus-host disease, and metabolic diseases .
1,10-Decanediol is a diol compound that can react with α-ketoglutarate (aKG) to generate polymeric microparticles (termed paKG MPs) for the sustained release of aKG, thereby promoting immunosuppressive regulation. Additionally, paKG MPs can bind to dendritic cells (DCs), reducing their glycolysis and mitochondrial respiration in vitro. These metabolic changes lead to the modulation of MHC-II and CD86 expression in DCs and alter the frequency of regulatoryTcells (Tregs) as well as T-helper type 1/2/17 cells in vitro. 1,10-Decanediol can be used in research within the field of immunometabolism. can be used as a surfactant/stabilizer in the synthesis of nanomaterials .
iST2-1 is an Stimulation-2 (ST2) inhibitor with an IC50 value of 46.65 μM, blocks interaction between ST2 and IL-33, inhibits downstream signaling. iST2-1 functions as an immunomodulator, reduces proliferation of CD4 + and CD8 +Tcells, increases regulatoryTcell populations, reduces IFN-γ +CD4 +Tcell populations, increases Foxp3 +CD4 +regulatoryTcell populations in the gastrointestinal tract. iST2-1 reduces plasma soluble ST2 and IFN-γ levels, reduces graft-versus-host disease scores, improves survival in graft-versus-host disease animal models, preserves graft-versus-tumor effect. iST2-1 can be used for the research of graft-versus-host disease .
GFH018 is an orally active, selective and ATP-competitive TGF-βR1 inhibitor with an IC50 of 40 nM. GFH018 reactivates the immune system by blocking the immunosuppression mediated by regulatoryTcells and M2 macrophages. GFH018 inhibits tumor angiogenesis. GFH018 suppresses tumor growth in mouse tumor models. GFH018 can be used for the research of solid tumors, hepatocellular carcinoma, colorectal cancer, breast cancer, and relapsed/metastatic nasopharyngeal carcinoma .
Isoallolithocholic acid (Standard) is the analytical standard of Isoallolithocholic acid. This product is intended for research and analytical applications. Isoallolithocholic acid (3β-Hydroxy-5α-cholanic acid), a derivative of Lithocholic acid (HY-10219), is a Tcellregulator. Isoallolithocholic acid enhances regulatoryTcells (Tregs) differentiation[1].
Anisperimus (LF-150195) is an immunosuppressant with the activity of enhancing activation-induced Tcell death. Anisperimus enhances the sensitivity of Tcells to anti-CD95 antibodies and other inducers by promoting the activation of caspase-8 and caspase-10 at the level of the death-inducing signaling complex (DISC). Anisperimus also promotes the development of Foxp3-expressing regulatory CD4 Tcells, thereby preventing central nervous system autoimmunity .
AZD8701 (IONIS-1063734) sodium is an antisense oligonucleotide targeting FOXP3 in regulatoryTcells (Tregs). AZD8701 sodium can relieve immunosuppression in cancer .
Efizonerimod alfa (MEDI-6383) is a recombinant human OX40L IgG4P Fc fusion protein that assembles into a hexameric structure and exerts potent agonist activity upon binding to OX40. The activity of Efizonerimod alfa is enhanced by Fcγ receptor-mediated aggregation. Efizonerimod alfa binds to OX40 on the surface of activated Tcells, induces NF-κB promoter activity in OX40-expressing Tcells, and triggers the production of Th1-type cytokines, Tcell proliferation, and resistance to regulatoryTcell (Treg)-mediated suppression. Efizonerimod alfa enhances the cytolytic activity of tumor-reactive Tcells and slows tumor growth in immunodeficient mice. Efizonerimod alfa induces the proliferation of CD4, CD8, and B cells in the peripheral blood of healthy non-human primates. Efizonerimod alfa can be used in the research of advanced solid malignancies and melanoma .
Human IL2RA mRNA encodes the human interleukin 2 receptor subunit alpha (IL2RA) protein, a receptor for interleukin-2. IL2RA is involved in the regulation of immune tolerance by controlling regulatoryTcells (TREGs) activity.
Anti-Mouse/Human KLRG-1 Antibody (2F1) is a Syrian hamster-derived IgG type antibody inhibitor, targeting to mouse/human KLRG-1. Anti-Mouse/Human KLRG-1 Antibody (2F1) neutralizes KLRG1. Anti-Mouse/Human KLRG-1 Antibody (2F1) reduces T-cell receptor signals and regulatoryT-cell accumulation. Anti-Mouse/Human KLRG-1 Antibody (2F1) can be used for the researches of immunology .
ASP-1948 is a human monoclonal antibody (mAb) targeting NRP1/VEGF165R/CD34. ASP-1948 reverses the suppressive effects of regulatoryTcells. ASP-1948 can be used in solid tumors research .
RORγt agonist 3 is a potent agonist of RORγt. RORγt agonist 3 promotes the differentiation of Th17 cells and enhances the levels of pro-inflammatory cytokines, thereby increasing the cytotoxicity of lymphocytes. RORγt agonist 3 inhibits the production of regulatoryTcells, which suppresses the immune response (extracted from patent WO2021136326A1, compound 23) .
RORγt agonist 2 is a potent agonist of RORγt. RORγt agonist 2 promotes the differentiation of Th17 cells and enhances the levels of pro-inflammatory cytokines, thereby increasing the cytotoxicity of lymphocytes. RORγt agonist 2 inhibits the production of regulatoryTcells, which suppresses the immune response (extracted from patent WO2021136339A1, compound 17) .
SR1555 hydrochloride is the hydrochloride salt form of SR1555 (HY-120785). SR1555 hydrochloride is an inverse agonist for retinoic acid receptor-related orphan nuclear receptor γ (RORγ) with an IC50 of 1 μM. SR1555 hydrochloride inhibits the development and function of pro-inflammatory TH17 cell, increases the frequency of anti-inflammatory Tregulatory (Treg) cells. SR1555 hydrochloride can be used for research about autoimmune diseases .
1,10-Decanediol-d20 is the deuterium labeled 1,10-Decanediol . 1,10-Decanediol is a diol compound that can react with α-ketoglutarate (aKG) to generate polymeric microparticles (termed paKG MPs) for the sustained release of aKG, thereby promoting immunosuppressive regulation. Additionally, paKG MPs can bind to dendritic cells (DCs), reducing their glycolysis and mitochondrial respiration in vitro. These metabolic changes lead to the modulation of MHC-II and CD86 expression in DCs and alter the frequency of regulatoryTcells (Tregs) as well as T-helper type 1/2/17 cells in vitro. 1,10-Decanediol can be used in research within the field of immunometabolism. can be used as a surfactant/stabilizer in the synthesis of nanomaterials .
SjDX5-53 is a selective TLR2 inducer derived from a 3 kDa peptide from Schistosoma japonicum eggs. SjDX5-53 inhibits inflammatory Th1 and Th17 responses by inducing tolerogenic dendritic cells (tolDCs) and promoting the generation of regulatoryTcells (Tregs) and their suppressive capacity. SjDX5-53 is primarily used in the treatment of autoimmune and inflammatory diseases such as colitis and psoriasis .
FB102 is an anti-human CD122 (IL-2Rβ) monoclonal antibody with selective activity. FB102 blocks the proliferation and activation of pathogenic NKcells and specific Tcell subsets induced by IL-2 and IL-15, without affecting the proliferation of regulatoryTcells. FB102 inhibits IL-2/IL-15-induced activation of CD4+ and CD8+ Tcells in in vitro disease models. FB102 is applicable to research related to celiac disease .
GIGA-564 is a fully human anti-CTLA4 IgG1 monoclonal antibody with a Kd of 9.8 nM. GIGA-564 binds to a unique epitope of CTLA-4, mediates FcR-dependent signaling pathways, depletes CTLA-4-highly-expressing regulatoryTcells within tumors, and inhibits the proliferation of peripheral regulatoryTcells. GIGA-564 exhibits anti-tumor activity in mouse models. GIGA-564 can be used for tumor research .
DS-1055a is an anti-human GARP antibody. DS-1055a effectively depletes GARP-positive regulatoryTcells in the tumor microenvironment, and activates effector Tcells. DS-1055a exhibits antitumor activity and can be used for the research of cancer, such as colon cancer .
IHCH-3185 is an orally active class I HDAC inhibitor (HDAC1 IC50 =102.9 nM) and A2AR antagonist (A2ARKi =7.6 nM). IHCH-3185 reverses immune gene silencing by inducing histone acetylation and blocks the adenosine signaling pathway to relieve T-cell suppression. IHCH-3185 exhibits antiproliferative activity, induces cell cycle arrest, and significantly improves the tumor microenvironment. IHCH-3185 reduces the proportion of regulatoryTcells, increases the CD8 +/Treg ratio, and upregulates the expression of key factors such as H2-K1, Cxcl9 and Cxcl10. IHCH-3185 shows significant antitumor potential in CT26 and MC38 mouse tumor models and is suitable for related cancer research .
SHR-1806 is a OX40 agonist and a NF-κB activator, with antitumor activity. SHR-1806 mediates ADCC and CDC effects, enhances the function and expansion of effector Tcells, suppresses regulatoryTcells, and increases γ-interferon secretion. SHR-1806 exhibits typical pharmacokinetic characteristics and favorable safety profiles. SHR-1806 can be used in studies related to solid tumors and colon cancer .
RO8323 is an orally active, selective CDK8/CDK19 inhibitor, with an IC50 of 2 nM against CDK8 and 3 nM against CDK19. RO8323 promotes regulatoryTcell differentiation, inhibits effector Tcell generation, reverses the Teff/Treg ratio, upregulates IL-10 production in myeloid cells, and suppresses the production of TNF-α, IL-6 and IL-12. RO8323 enhances immune reconstitution and prolongs cardiac allograft survival in a dose-dependent manner. RO8323 can be used in the research of chronic graft-versus-host disease, cardiac allograft rejection, acute graft-versus-host disease and experimental autoimmune encephalomyelitis .
REGN6569 is a fully human IgG1 monoclonal antibody targeting glucocorticoid-induced tumor necrosis factor receptor-related protein (GITR) with high specificity for GITR. REGN6569 exerts stronger in vitro antibody-dependent cell-mediated cytotoxicity (ADCC) against regulatoryTcells expressing GITR. REGN6569 selectively depletes regulatoryTcells via antibody-dependent cell-mediated cytotoxicity and increases the proportion of proliferative natural killer (NK) cells in peripheral blood. REGN6569 is applicable for advanced solid malignancies. Isotype control: HY-P99001 .
10 (11)-Cl-BBQ is a high-affinity aryl hydrocarbon receptor (AhR) agonist. 10 (11)-Cl-BBQ is a mixture of 10-Cl-BBQ and 11-Cl-BBQ, among which 11-Cl-BBQ exhibits higher AhR activation potency than 10-Cl-BBQ. Low-dose/short-term AhR activation by 10 (11)-Cl-BBQ promotes IL-17 production, while high-dose/sustained activation induces regulatoryTcells and suppresses immune responses. 10 (11)-Cl-BBQ can be used in immunomodulation research .
JNJ-64164711 (JNJ-711) is a bifunctional antibody that simultaneously targets human GITR/TNFRSF18 and FcγRIIIa. JNJ-64164711 binds to the GITR domain to activate the NF-κB signaling pathway, while binding to FcγRIIIa to support antibody-dependent cellular cytotoxicity (ADCC). JNJ-64164711 can specifically eliminate GITR-positive hematological tumor cells, activated Tcells and intratumoral regulatoryTcells through the ADCC mechanism, thereby significantly enhancing the body's anti-tumor immune response. JNJ-64164711 can be used in research related to non-small cell lung cancer, colorectal cancer, prostate cancer, renal cell carcinoma and hematological tumors .
HB0030 is a TIGIT inhibitor with antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) activities. HB0030 enhances the expression of activation markers in natural killer (NK) cells, promotes the killing of regulatoryTcells (Tregs), and reduces the proportion of FoxP3 +Treg in tumor-infiltrating lymphocytes. The combination of HB0030 with the anti-PD-L1/VEGF bispecific antibody HB0025 further enhances tumor suppression efficacy. HB0030 can be used in studies related to colorectal cancer, pancreatic adenocarcinoma, hepatocellular carcinoma, bladder cancer, breast cancer, non-small cell lung cancer, and advanced solid tumors .
IKZF2-degrader 5 is a highly efficient, highly selective, rapidly acting, and orally active IKZF2 molecular glue degrader. IKZF2-degrader 5 induces IKZF2 degradation via the Cullin-CRBN-dependent pathway. IKZF2-degrader 5 promotes the production of pro-inflammatory IL-2. IKZF2-degrader 5 attenuates the immunosuppressive function of regulatoryTcells (Tregs). IKZF2-degrader 5 triggers rapid, significant, and sustained IKZF2 degradation in the spleen and thymus of mice. IKZF2-degrader 5 inhibits tumor growth. IKZF2-degrader 5 can be used for the research of B16F melanoma .
Anti-ZnT8 Antibody (mAb43) is a monoclonal antibody targeting the zinc transporter ZnT8, with islet-specific biodistribution characteristics. Anti-ZnT8 Antibody (mAb43) binds to extracellular ZnT8 on the surface of pancreatic β-cells and masks its insulin-co-localizing sites to block autoimmune recognition. Anti-ZnT8 Antibody (mAb43) also promotes an increase in the proportion of regulatoryTcells and inhibits B cell antigen presentation, thereby effectively blocking the Tcell-mediated cascade of β-cell destruction. Anti-ZnT8 Antibody (mAb43) eliminates insulitis, preserves β-cell mass and induces seroconversion of autoantibodies, without directly altering the insulin secretion function or content of β-cells. Anti-ZnT8 Antibody (mAb43) can be used for research related to type 1 diabetes .
HLX51 is a regulatoryTcell inhibitor and OX40/CD134/TNFRSF4 agonist with tumour growth inhibitory activity. HLX51 inhibits regulatoryTcell differentiation and activity, relieves tumour microenvironment immunosuppression, enhances effector Tcell function. HLX51 competitively binds OX40, activates OX40, promotes immune cell proliferation and Tcell killing ability. HLX51 modulates immune cell function to inhibit tumour growth. HLX51 can be used for the research of advanced/metastatic solid tumours and lymphomas .
OX118 is a fully human, ADCC-enhanced monoclonal antibody targeting OX40L, the recommended isotype control is HY-P99001. OX118 blocks OX40L, suppresses effector T-cell proliferation, expands regulatoryT-cell populations, and reduces bystander activation across natural killer cells, B cells, and CD14+ monocytes. OX118 can be used for the research of graft-versus-host disease .
Necroptosis inducer 1 is a necroptosis inducer. Necroptosis inducer 1 inhibits the activity of thioredoxin reductase (TrxR), elevates intracellular ROS levels, triggers ROS-mediated necroptosis, and induces necroptosis-dependent immunogenic cell death. Necroptosis inducer 1 inhibits tumor growth, remodels the tumor immune microenvironment, and exerts a synergistic effect with anti-PD-1 in animal models. Necroptosis inducer 1 is applicable to the research of colon cancer .
YH004 is an anti-CD137 agonistic monoclonal antibody, with immunostimulating and antineoplastic activities. YH004 activates CD137 expressed on a variety of leukocyte subsets including activated T lymphocytes and natural killer cells. YH004 enhances CD137-mediated signaling and induces cytotoxic T-lymphocyte (CTL) proliferation, cytokine production and promotes anti-tumor response mediated by CTL. YH004 induces NK-mediated tumor cell killing and suppresses the immunosuppressive activity of regulatoryTcells. YH004 can be studied in anticancer research .
Anti-Mouse CD4 Antibody (YTS 177) reacts with the mouse CD4. Anti-Mouse CD4 Antibody (YTS 177) shows non-depleting but binding does induce rapid internalization of CD4 on both CD4 + Foxp3- Tcells and Foxp3 +regulatoryTcells. Recommend Isotype Controls: Rat IgG2a kappa, Isotype Control (HY-P990679) .
Sotrastaurin (AEB071) acetate is a selective, orally active PKC inhibitor. Sotrastaurin acetate inactivates NF-κB by inhibiting PKC α, β, θ, γ subtypes, thereby reducing the transcription levels of immune response-related genes. Sotrastaurin acetate effectively inhibits alloreactive Tcell proliferation, conventional Tcell activation, as well as the production of pro-inflammatory cytokines and B lymphocytes. Sotrastaurin acetate also maintains the functional and phenotypic stability of regulatoryTcells, enhances Foxp3 expression and restores the balance of helper T lymphocytes. Sotrastaurin acetate can prolong the survival time of allografts, and alleviate inflammatory responses and myasthenic symptoms by reducing anti-AChR antibody levels. Sotrastaurin acetate is widely used in studies related to kidney transplantation, psoriasis and myasthenia gravis .
RTX-003 is a monoclonal antibody targeting CD25. RTX-003 induces the death of regulatoryTcells (Tregs) by targeting the IL-2 receptor α chain (CD25), and can enhance anti-tumor immune responses.
Fa-Au is a TrxR inhibitor. Fa-Au downregulates GPX4, induces oxidative stress, mitochondria-associated ferroptosis (ferroptosis) and immunogenic cell death. Fa-Au induces ROS production in hepatoma cells. Fa-Au remodels the tumor immune microenvironment via M1 macrophage polarization, dendritic cell maturation, CD8+Tcell activation and reduction of regulatoryTcells. Fa-Au induces an anti-tumor immune feedback loop through the IFNγ/STAT1/SLC7A11 axis. Fa-Au inhibits tumor growth. Fa-Au is applicable to hepatocellular carcinoma-related research .
IIIM1 is an orally active anti-inflammatory peptide. IIIM1 ameliorates the symptoms of experimental autoimmune encephalomyelitis (EAE) by stimulating the proliferation of regulatoryTcells and inducing them to produce RA1, and regulating the cytokine balance. IIIM1 can be used in the research of multiple sclerosis (MS) .
DS-1055a (FUT8-KO) is an anti-human GARP antibody that has knocked out the fucosyltransferase 8 gene (FUT8). It exhibits enhanced antibody-mediated cytotoxicity (ADCC) effect. DS-1055a (FUT8-KO) can effectively eliminate GARP-positive regulatoryTcells in the tumor microenvironment and activate effector Tcells. DS-1055a (FUT8-KO) has anti-tumor activity and can be used in cancer research (such as colon cancer) .
PLT012 is a humanized IgG4 antibody targeting CD36. PLT012 inhibits the lipid-binding domain of CD36. PLT012 blocks CD36-mediated metabolic adaptation in regulatoryTcells (Tregs) and CD8 + tumor-infiltrating lymphocytes (TILs), thereby inhibiting tumor growth and shifting the tumor microenvironment from immunosuppressive to immunosupportive. PLT012 reduces intratumoral Tregs, enhances CD8 +Tcell infiltration and cytotoxic function, and increases the abundance of progenitor-exhausted Tcells. PLT012 exerts robust antitumor activity and synergizes with anti-PD-L1 or standard-of-care regimens (anti-VEGF + anti-PD-L1). PLT012 can be used for hepatocellular carcinoma, colorectal cancer and solid tumor research .
HFB200901 is a galectin LGALS9 inhibitor and immunostimulant that can be used in studies related to pancreatic adenocarcinoma, pancreatic intraepithelial neoplasia, KRAS G12C-mutant colon cancer, and prostate cancer. HFB200901 disrupts the LGALS9/TIM-3 axis, while blocking the internalization and vacuolization of recombinant LGALS9. HFB200901 reduces the proportion of regulatoryTcells (Treg) and enhances dendritic cell activation, thereby inducing polyfunctional and memory CD8 +Tcell responses. HFB200901 inhibits the progression of pancreatic neoplastic lesions and effectively improves the efficacy of PSMA-based vaccination .
DPMI-ω is a dual-specificity d-peptide antagonist of oncogenic proteins MDM2 and MDMX. DPMI-ω, upon fabrication on gold nanoparticles, efficiently traverses tumor cells and kills them by reactivating the p53 signaling pathway. DPMI-ω can disrupte the p53-MDM2/MDMX complex. DPMI-ω can inhibit B16 melanoma growth and induce cells G0/G1 phase arrest. DPMI-ω can augment the efficacy of immunotherapy by expanding CD3 +/CD8 + cytotoxic Tcells and suppressing CD4 +/CD25 +regulatoryTcells companied with anti-PD1 antibody. DPMI-ω can be used for research of melanoma .
Anti-Human/Mouse LY6E Antibody (9B12) is a high-affinity, multi-target antibody that binds specifically to LY6E. Anti-Human/Mouse LY6E Antibody (9B12) binds specifically to cell-surface LY6E and enters lysosomes via lipid raft-dependent endocytosis, thereby effectively inhibiting the growth of various LY6E-expressing solid tumors (such as breast cancer and lung cancer) in both in vitro and in vivo models. Anti-Human/Mouse LY6E Antibody (9B12) exerts a dual mechanism of action: on one hand, it blocks the interaction between PILRα and CD8α, specifically reduces the survival rate of peripheral CD8 +Tcells and induces their activation, breaking the state of cellular quiescence; on the other hand, it recognizes and immunoprecipitates IDE under both non-denaturing and denaturing conditions, which is applicable to studies on the subcellular localization and protein interactions of IDE. The regulatory effect of Anti-Human/Mouse LY6E Antibody (9B12) on CD8 +Tcells strictly depends on the presence of PILRα, and it does not affect CD4 +Tcells or Tcell development in the thymus, exhibiting high specificity .
ODN 1668, a class B CpG ODN (oligodeoxynucleotide), is a TLR-9 agonist. ODN 1668 has strong immune regulatory properties, can enhance the level of antibody IgG2 subtype, promote the immune response of Tcells and B cells, and can be used in the study of vaccine adjuvants. In addition, CpG ODN 1668 induces an antimicrobial immune response via a CaTLR9 dependent pathway in groupers. Sequence: 5'-tccatgacgttcctgatgct-3’ .
ODN 1668 sodium, a class B CpG ODN (oligodeoxynucleotide), is a TLR-9 agonist. ODN 1668 sodium has strong immune regulatory properties, can enhance the level of antibody IgG2 subtype, promote the immune response of Tcells and B cells, and can be used in the study of vaccine adjuvants. In addition, CpG ODN 1668 sodium induces an antimicrobial immune response via a CaTLR9 dependent pathway in groupers. Sequence: 5'-tccatgacgttcctgatgct-3’ .
PSMα3 is an inhibitor of NF-κB p65 and p38 MAPK. PSMα3 forms membrane pores and binds to residues of human insulin B chain to inhibit insulin aggregation. PSMα3 forms α-type amyloid-like fibrils to exert cytotoxic effects, and acts as a functional amyloid virulence determinant of Staphylococcus aureus. PSMα3 is applicable to research related to spondyloarthritis, rheumatoid arthritis, insulin-derived amyloidosis, and Staphylococcus aureus infection .
AH-D peptide is a brain-penetrant antiviral agent disrupting highly curved lipid membranes. AH-D peptide exhibits broad-spectrum antiviral activity against ZIKV, Dengue virus, Chikungunya virus, yellow fever virus and Japanese encephalitis virus, with IC50 values of 11.9, 12.5, 35.7, 206 and 136 nM, respectively. AH-D peptide reduces the viral load in the brain, suppresses inflammation, protects neurons, and does not damage the blood brain barrier. AH-D peptide restores antitumor immunity by decreasing circulating PD-L1 + exosomes, reducing intratumoral immunosuppressive cells (regulatoryTcells, myeloid-derived suppressor cells), and enhancing Tcell function. AH-D peptide inhibits membrane-enveloped viruses and cancer cell metastasis in vivo. AH-D peptide exhibits no immunogenicity and has negligible effects on normal tissues. AH-D peptide can be used for research in Zika virus and other mosquito-borne viruses, cancer immunotherapy and metastasis .
SjDX5-53 control peptide is a control peptide of the TLR2 activator SjDX5-53 (HY-P10982) that does not target a specific receptor and does not modulate regulatoryTcells (Tregs) or dendritic cells. SjDX5-53 control peptide can be used to exclude nonspecific effects and help verify the specific role of SjDX5-53 in inducing Tregs and alleviating autoimmune diseases. SjDX5-53 control peptide is used in the study of autoimmune diseases such as colitis and psoriasis .
AS2863619 GMP is AS2863619 (HY-126675) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. AS2863619 is an orally active CDK8/19 inhibitor that also inhibits BMP2, MDA5 and RIG-I receptors. AS2863619 targets Stat5a-CDK8/19 to promote the differentiation of CD4 +Tcells into regulatoryTcells and induce FOXP3 expression, thereby restoring immune homeostasis and establishing transplant immune tolerance. AS2863619 also enhances the BMP2/SMAD signaling pathway to promote osteogenic differentiation and inhibit adipogenic differentiation. AS2863619 exerts osteoprotective effects by alleviating inflammation-induced impairment of osteogenic function and inducing neutrophil apoptosis (apoptosis). AS2863619 can be applied to research in related fields such as periodontitis-induced bone defects .
ST45177901 is a CC chemokine receptor 4 (CCR4) antagonist. The combination of ST45177901 and Sorafenib (HY-10201) effectively inhibits the chemotaxis of Treg cells via the CCL22/CCL17-CCR4 signaling pathway, thereby significantly suppressing the growth and metastasis of tumor cells. ST45177901 is applicable to liver cancer research .
SS47 TFA, a PROTAC-based HPK1 degrader, exerts proteasome-mediated HPK1 degradation. The degradation of HPK1 via SS47 also significantly enhances the in vivo antitumor efficacy of BCMA CAR-Tcell research. HPK1, an immunosuppressive regulatory kinase, is a promising target for cancer immunotherapies . SS47 (TFA) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
Vatelizumab (GBR500) is a monoclonal antibody that targets the α2 subunit (CD49b) of very late antigen 2 (VLA-2). Vatelizumab can be used for research on multiple sclerosis .
ZL-1218 is a selective humanized IgG1 antibody, targeting CCR8. ZL-1218 induces antibody-dependent cellular cytotoxicity (ADCC), leading to NK cell-mediated depletion of CCR8-expressing regulatoryTcells (Tregs). ZL-1218 blocks the binding of the CCR8 ligand CCL1 to CCR8 and reduces Treg recruitment by inhibiting the chemotaxis of CCR8 +cells. ZL-1218 reduces intratumoral Treg levels in a dose-dependent manner. ZL-1218 exerts enhanced antitumor activity when combined with the anti-PD-1 antibody. ZL-1218 can be used for solid tumour research .
Anti-Mouse CD3ε Antibody (145-2C11) is an orally active anti-mouse CD3ε IgG1 monoclonal antibody. Anti-Mouse CD3ε Antibody (145-2C11) can inhibit the proliferation of effector Tcells and improve the function of regulatoryTcells (Tregs). Anti-Mouse CD3ε Antibody (145-2C11) relieves inflammatory response by inhibiting the production of pro-inflammatory cytokines and increasing the secretion of anti-inflammatory factors. Anti-Mouse CD3ε Antibody (145-2C11) can be used for researches on metabolic and immune system conditions such as diabetes and lupus. The recommend isotype control of Anti-Mouse CD3ε Antibody (145-2C11): Armenian hamster IgG, Isotype Control (HY-P990305) .
FTI-277 TFA is a farnesyltransferase (FTase) inhibitor. FTI-277 TFA inhibits Ras farnesylation, blocks the phosphorylation of downstream ERK1/2 and mTOR, and reduces membrane-bound active N-ras protein. FTI-277 TFA activates caspase 3, upregulates Bim expression, induces cellapoptosis, suppresses regulatoryTcell expansion, enhances macrophage phagocytosis, and improves bacterial clearance. FTI-277 TFA activates the PI3K/Akt signaling pathway, inhibits osteoblast differentiation, and reduces the proliferation ability of neuroblastoma cells. FTI-277 TFA can be used in research related to head and neck squamous cell carcinoma, neuroblastoma, sepsis, and vascular calcification .
GSK2618960 is a human monoclonal antibody (mAb) targeting IL-7Ra/CD127. GSK2618960 inhibits IL-7-induced STAT5 phosphorylation. GSK2618960 enhances CD4 T cell proliferation response and increases CD83, CD86, and CD209 expression in PBMCs. GSK2618960 can be used for the research of autoimmune and allergic inflammatory diseases. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
C5F2-HCB is a CYP-mediated inhibitor of the biosynthesis of arachidonic acid epoxygenase product (±) 14,15-EET (HY-150084), with an IC50 of 3.1 μM. C5F2-HCB inhibits EET-driven oxidative phosphorylation (OXPHOS) associated with tumor hypoxia, converting an immunologically "cold" tumor microenvironment into a "hot" one. C5F2-HCB reverses the immune-excluded tumor microenvironment in ER +HER2 − breast cancer allograft models. C5F2-HCB can be used in research related to ER +HER2 − breast cancer .
Cusatuzumab (ARGX-110) is a selective competitive blocker targeting CD70 (with an equilibrium dissociation constant of 17 pM for binding to human CD70). Cusatuzumab also possesses enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) activity. It is a humanized IgG1 monoclonal antibody, artificially synthesized through humanization and genetic engineering modifications (CH2 region mutation to enhance effector function). Cusatuzumab has a dual mechanism of action: firstly, it competitively blocks the interaction between CD70 and CD27, inhibiting the CD27-NF-κB signaling pathway, reducing regulatoryTcell (Treg) activation and tumor cell proliferation; secondly, by enhancing binding to FcγRIIIa, it mediates ADCC and antibody-dependent cellular phagocytosis (ADCP), directly lysing CD70-positive tumor cells. Cusatuzumab can efficiently eliminate leukemia stem cells (LSCs), induce tumor cell differentiation and apoptosis, restore immune surveillance, and target CD70-positive tumors. Cusatuzumab is used in the study of acute myeloid leukemia (AML) .
MRL20 is a PPARγ constitutive and allosteric agonist. MRL20 enhances the interaction between PPARγ and the co-activating peptide of TRAP220, with its EC50 being 10 nM. Even after being covalently blocked in the constitutive pocket by GW9662 (HY-16578) or T0070907 (HY-13202), MRL20 can still strengthen the interaction between PPARγ and TRAP220, with EC50 values of 176 and 440 nM respectively. MRL20 fails to completely inhibit its cell activation effect. MRL20 can be used to study the allosteric regulatory mechanism of PPARγ .
Theralizumab (TGN1412) is a humanized lgG4 superagonistic anti-CD28 monoclonal antibody that directly stimulates T cells. Theralizumab can cause cytokine release syndrome (CRS). Theralizumab can be used for the research of rheumatoid arthritis .
Mucinase StcE is a zinc metalloproteinase belonging to the M66 family, which is secreted by enterohemorrhagic Escherichia coli via the type II general secretion pathway. Mucinase StcE specifically recognizes and cleaves the 'T*XT' motif in mucin-type glycoproteins with α-O-glycans (such as MUC2, Mucin 7, Glycoprotein 340, CD45, CD43, C1 Esterase Inhibitor (HY-P991629), etc.). By degrading the mucus layer to reduce its viscosity, inhibiting complement cascade activation, and localizing complement regulatory factors to the cell membrane, Mucinase StcE helps bacteria penetrate the mucosal barrier, adhere to host cells, and evade immune clearance. Mucinase StcE can serve as a mucin-specific proteolytic tool for research on mucinous carcinomas derived from the colon, esophagus, and salivary glands .
TNX-1500 is a crystallizable fragment-modified anti-CD154 antibody. TNX-1500 contains the hu5c8 fragment antigen-binding (Fab) domain from Ruplizumab (HY-P99315) and an IgG4 Fc region engineered to reduce FcγRIIa binding. TNX-1500 has significantly weaker binding affinity to FcγRI, FcγRIIaH, FcγRIIbF, FcγRIIIaF, and FcγRIIIaV compared to hu5c8 (Kdvalues: 8.7 nM, 7100 nM, 4900 nM, 8000 nM, 6000 nM respectively). TNX-1500 prolongs nonhuman primate renal allograft survival, prolongs nonhuman primate cardiac allograft survival. TNX-1500 can be used for the research of allograft rejection [1][2].
Anti-Mouse ICOS Antibody (7E.17G9) is a mouse ICOS agonist IgG2b monoclonal antibody. Anti-Mouse ICOS Antibody (7E.17G9) can upregulate ICOS expression and enhance Tcell function. Anti-Mouse ICOS Antibody (7E.17G9) can significantly inhibit the immune regulatory function of dendritic cells (DCs). Anti-Mouse ICOS Antibody (7E.17G9) can eliminate transplant tolerance. Anti-Mouse ICOS Antibody (7E.17G9) can be used for researches on inflammation conditions, cancer and xenotransplantation such as nephritis and pancreatic cancer .
JMJD1C-IN-1 is an orally active and selective inhibitor of JMJD1C (IC50= 0.59 μM, Kd = 1.96 μM). JMJD1C-IN-1 inhibits the binding of JMJD1C to H3K9me2 peptide substrate in the HTRF assay (IC50 = 1.47 μM). JMJD1C-IN-1 disrupts intratumoral regulatoryT (Treg) cell fitness by dual mechanisms: promoting H3K9me2 accumulation to downregulate PD1 expression and reducing STAT3 demethylation to enhance STAT3 activation. JMJD1C-IN-1 demonstrates dose-dependent antitumor efficacy in multiple mouse tumor models (MCA205 fibrosarcoma, B16-F10 melanoma, LLC lung cancer, Hepa1-6 hepatocellular carcinoma, CT26 colorectal cancer). JMJD1C-IN-1 can be used for the study of tumor immunotherapy by selectively targeting intratumoral Treg cells .
AS2863619 GMP is AS2863619 (HY-126675) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. AS2863619 is an orally active CDK8/19 inhibitor that also inhibits BMP2, MDA5 and RIG-I receptors. AS2863619 targets Stat5a-CDK8/19 to promote the differentiation of CD4 +Tcells into regulatoryTcells and induce FOXP3 expression, thereby restoring immune homeostasis and establishing transplant immune tolerance. AS2863619 also enhances the BMP2/SMAD signaling pathway to promote osteogenic differentiation and inhibit adipogenic differentiation. AS2863619 exerts osteoprotective effects by alleviating inflammation-induced impairment of osteogenic function and inducing neutrophil apoptosis (apoptosis). AS2863619 can be applied to research in related fields such as periodontitis-induced bone defects .
AS2863619 GMP is AS2863619 (HY-126675) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. AS2863619 is an orally active CDK8/19 inhibitor that also inhibits BMP2, MDA5 and RIG-I receptors. AS2863619 targets Stat5a-CDK8/19 to promote the differentiation of CD4 +Tcells into regulatoryTcells and induce FOXP3 expression, thereby restoring immune homeostasis and establishing transplant immune tolerance. AS2863619 also enhances the BMP2/SMAD signaling pathway to promote osteogenic differentiation and inhibit adipogenic differentiation. AS2863619 exerts osteoprotective effects by alleviating inflammation-induced impairment of osteogenic function and inducing neutrophil apoptosis (apoptosis). AS2863619 can be applied to research in related fields such as periodontitis-induced bone defects .
PSMα3 is an inhibitor of NF-κB p65 and p38 MAPK. PSMα3 forms membrane pores and binds to residues of human insulin B chain to inhibit insulin aggregation. PSMα3 forms α-type amyloid-like fibrils to exert cytotoxic effects, and acts as a functional amyloid virulence determinant of Staphylococcus aureus. PSMα3 is applicable to research related to spondyloarthritis, rheumatoid arthritis, insulin-derived amyloidosis, and Staphylococcus aureus infection .
PPACK TFA is an orally active, selective molecular glue degrader targeting IKZF2. Through a molecular glue mechanism, PPACK TFA binds to CRBN, recruits IKZF2 to form a ternary complex, and promotes its ubiquitination and proteasomal degradation. This further converts inhibitory regulatoryTcells (Treg) into effector-like Tcells, enhances CD8 +Tcell responses, and modulates the Teff:Treg balance. PPACK TFA also increases the production of the inflammatory cytokine IL-2 and reduces the suppressive activity of Treg. PPACK TFA can be used in cancer immunotherapy research, and exhibits a synergistic effect when combined with immune checkpoint inhibitors such as anti-PD1 .
Peptide P60 is a FOXP3 inhibitor. Peptide P60 reduces the nuclear translocation of FOXP3 and impairs FOXP3-mediated inhibition of NF-κB and NFAT activity. Peptide P60 inhibits the immunosuppressive activity of regulatoryTcells and restores the proliferation and activation of effector Tcells. Peptide P60 induces lymphoproliferative autoimmune syndrome in neonatal ICR mice and reduces the number of CD4 +CD25 +Foxp3 +Tcells in the spleen. Peptide P60 enhances the efficacy of AH1 (HY-P4193) peptide vaccine and recombinant adenovirus-based HCV NS3 vaccine in BALB/c mice, including protective effects against CT26 tumor implantation. Peptide P60 can be used in studies related to tumor immunity, viral infection and lymphoproliferative autoimmune syndrome .
AH-D peptide is a brain-penetrant antiviral agent disrupting highly curved lipid membranes. AH-D peptide exhibits broad-spectrum antiviral activity against ZIKV, Dengue virus, Chikungunya virus, yellow fever virus and Japanese encephalitis virus, with IC50 values of 11.9, 12.5, 35.7, 206 and 136 nM, respectively. AH-D peptide reduces the viral load in the brain, suppresses inflammation, protects neurons, and does not damage the blood brain barrier. AH-D peptide restores antitumor immunity by decreasing circulating PD-L1 + exosomes, reducing intratumoral immunosuppressive cells (regulatoryTcells, myeloid-derived suppressor cells), and enhancing Tcell function. AH-D peptide inhibits membrane-enveloped viruses and cancer cell metastasis in vivo. AH-D peptide exhibits no immunogenicity and has negligible effects on normal tissues. AH-D peptide can be used for research in Zika virus and other mosquito-borne viruses, cancer immunotherapy and metastasis .
IT9302 is a synthetic IL-10 agonist with the activity of inducing tolerogenic dendritic cells. IT9302 is able to mimic multiple effects of IL-10, including downregulating the antigen presentation machinery and increasing the sensitivity of tumor cells to natural killer cell-mediated lysis. IT9302 can also hinder the response of human monocytes to differentiation factors and reduce the antigen presentation and co-stimulatory capacity of dendritic cells. Dendritic cells treated with IT9302 showed a weakened ability to stimulate Tcell proliferation and interferon-γ production. IT9302 exerts its effects through mechanisms that are partially different from IL-10, involving STAT3 inactivation and regulation of the NF-κB intracellular pathway. IT9302-treated dendritic cells showed enhanced expression of membrane-bound TGF-β, associated with the effective induction of foxp3+ regulatoryTcells .
SjDX5-53 is a selective TLR2 inducer derived from a 3 kDa peptide from Schistosoma japonicum eggs. SjDX5-53 inhibits inflammatory Th1 and Th17 responses by inducing tolerogenic dendritic cells (tolDCs) and promoting the generation of regulatoryTcells (Tregs) and their suppressive capacity. SjDX5-53 is primarily used in the treatment of autoimmune and inflammatory diseases such as colitis and psoriasis .
Tregitope 289 is a peptide derived from the Fc region of immunoglobulin G (IgG) and is a highly conserved Tcell epitope that stimulates the expansion of natural regulatoryTcells. Co-delivery of Tregitope 289 with type 1 diabetes (T1D) antigens delays the development of hyperglycemia and reduces the incidence of diabetes in the NOD mouse model. Tregitope 289 can be used to study T1D and other autoimmune diseases .
IIIM1 is an orally active anti-inflammatory peptide. IIIM1 ameliorates the symptoms of experimental autoimmune encephalomyelitis (EAE) by stimulating the proliferation of regulatoryTcells and inducing them to produce RA1, and regulating the cytokine balance. IIIM1 can be used in the research of multiple sclerosis (MS) .
DPMI-ω is a dual-specificity d-peptide antagonist of oncogenic proteins MDM2 and MDMX. DPMI-ω, upon fabrication on gold nanoparticles, efficiently traverses tumor cells and kills them by reactivating the p53 signaling pathway. DPMI-ω can disrupte the p53-MDM2/MDMX complex. DPMI-ω can inhibit B16 melanoma growth and induce cells G0/G1 phase arrest. DPMI-ω can augment the efficacy of immunotherapy by expanding CD3 +/CD8 + cytotoxic Tcells and suppressing CD4 +/CD25 +regulatoryTcells companied with anti-PD1 antibody. DPMI-ω can be used for research of melanoma .
SjDX5-53 control peptide is a control peptide of the TLR2 activator SjDX5-53 (HY-P10982) that does not target a specific receptor and does not modulate regulatoryTcells (Tregs) or dendritic cells. SjDX5-53 control peptide can be used to exclude nonspecific effects and help verify the specific role of SjDX5-53 in inducing Tregs and alleviating autoimmune diseases. SjDX5-53 control peptide is used in the study of autoimmune diseases such as colitis and psoriasis .
Theralizumab (TGN1412) is a humanized lgG4 superagonistic anti-CD28 monoclonal antibody that directly stimulates T cells. Theralizumab can cause cytokine release syndrome (CRS). Theralizumab can be used for the research of rheumatoid arthritis .
Alemtuzumab (Campath-IH) is a humanized monoclonal antibody against CD52. Alemtuzumab does not cross-react with murine CD52. Alemtuzumab selectively targets the CD52 antigen to induce profound lymphocyte depletion, followed by recovery of T and B cells with regulatory phenotypes. Alemtuzumab is capable of complement-dependent cytotoxicity and antibody-dependent cell-mediated cytotoxicity (ADCC), as well as induction of apoptosis. Alemtuzumab has the potential for B-cell chronic lymphocytic leukaemia research .
Cusatuzumab (ARGX-110) is a selective competitive blocker targeting CD70 (with an equilibrium dissociation constant of 17 pM for binding to human CD70). Cusatuzumab also possesses enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) activity. It is a humanized IgG1 monoclonal antibody, artificially synthesized through humanization and genetic engineering modifications (CH2 region mutation to enhance effector function). Cusatuzumab has a dual mechanism of action: firstly, it competitively blocks the interaction between CD70 and CD27, inhibiting the CD27-NF-κB signaling pathway, reducing regulatoryTcell (Treg) activation and tumor cell proliferation; secondly, by enhancing binding to FcγRIIIa, it mediates ADCC and antibody-dependent cellular phagocytosis (ADCP), directly lysing CD70-positive tumor cells. Cusatuzumab can efficiently eliminate leukemia stem cells (LSCs), induce tumor cell differentiation and apoptosis, restore immune surveillance, and target CD70-positive tumors. Cusatuzumab is used in the study of acute myeloid leukemia (AML) .
Anti-Mouse CTLA-4 Antibody (9D9) is an anti-mouse CTLA-4 IgG2b monoclonal antibody. Anti-Mouse CTLA-4 Antibody (9D9) can bind to CTLA-4 and block its binding to B7. Anti-Mouse CTLA-4 Antibody (9D9) enhances Tcell function by increasing the ratio of CD8 +Tcells to regulatoryTcells (Tregs). Anti-Mouse CTLA-4 Antibody (9D9) can be used for research on cancer such as colon cancer and melanoma .
Ficerafusp alfa (BCA-101) is a bispecific antibody targeting EGFR and TGFβ, with a Kd of 2.58 nM against EGFR and a Kd of 61.3 nM against TGFβ1. Ficerafusp alfa binds to EGFR, inhibits EGFR phosphorylation, blocks EGF-dependent cell proliferation, and mediates antibody-dependent cellular cytotoxicity against EGFR-positive tumor cells. Ficerafusp alfa sequesters TGFβ via its TGFβRII ECD domain, neutralizes the activity of TGFβ and TGFβ1, and blocks TGFβ-dependent processes, including epithelial-mesenchymal transition, cell invasion, and differentiation of inducible regulatoryTcells. Ficerafusp alfa is applicable to research related to head and neck squamous cell carcinoma, advanced solid tumors, squamous non-small cell lung cancer, anal squamous cell carcinoma, colorectal cancer, and pancreatic cancer .
Siplizumab (MEDI-507) is a humanized IgG1 monoclonal antibody against CD2. Siplizumab depletes Tcells, decreases Tcell activation, inhibites Tcell proliferation and enriches naïve and bona fideregulatoryTcells .
Ligelizumab (QGE 031) is a humanized high-affinity anti-immunoglobulin IgE monoclonal antibody. Ligelizumab selectively inhibits the binding of IgE to the high-affinity receptor FcεRI, while the inhibitory effect on the low-affinity receptor CD23 is weak. Ligelizumab can inhibit the activation of effector cells such as mast cells and Basophil, while reducing the production of IgE by B cells, and restoring the IFN-α production and regulatoryTcell (Treg) induction function of plasmacytoid dendritic cells (pDC). Ligelizumab can be used in the study of allergic diseases (such as chronic spontaneous urticaria, allergic asthma) .
Melredableukin alfa (RG7835) is a bivalent conjugate composed of a human IL-2 mutant (T3A, N88D, C125A) and human IgG1. Melredableukin alfa exhibits enhanced Treg cell selectivity in cynomolgus monkey and humanized mouse models. Melredableukin alfa can be used in research related to ulcerative colitis and autoimmune hepatitis .
Daclizumab (Ro 24-7375) is a humanized, monoclonal antibody that blocks CD25 (α-subunit of the high-affinity interleukin-2 receptor (IL-2R-HA)). Daclizumab inhibits effector Tcell activation, regulatoryTcell (Treg) expansion and survival, and activation-induced T-cellapoptosis. Daclizumab increases IL-2 bioavailability to bind to the intermediate-affinity IL-2R (IL-2R-IA), driving the expansion of anti-inflammatory CD56bright natural killer (NK) cells. Daclizumab can be used for multiple sclerosis and cancer research .
Anti-Mouse CD3ε Antibody (145-2C11) is an orally active anti-mouse CD3ε IgG1 monoclonal antibody. Anti-Mouse CD3ε Antibody (145-2C11) can inhibit the proliferation of effector Tcells and improve the function of regulatoryTcells (Tregs). Anti-Mouse CD3ε Antibody (145-2C11) relieves inflammatory response by inhibiting the production of pro-inflammatory cytokines and increasing the secretion of anti-inflammatory factors. Anti-Mouse CD3ε Antibody (145-2C11) can be used for researches on metabolic and immune system conditions such as diabetes and lupus. The recommend isotype control of Anti-Mouse CD3ε Antibody (145-2C11): Armenian hamster IgG, Isotype Control (HY-P990305) .
Gotistobart (ONC-392; BNT 316) is a humanized anti-CTLA-4 antibody with selective regulatoryTcell depletion activity in the tumor microenvironment. Gotistobart can be used for the research of cancer, such as non-small cell lung cancer .
Ivuxolimab is a fully human IgG2 agonist targeting OX40 (CD134), which selectively binds to the OX40 receptor on the surface of activated CD4 + and CD8 +Tcells without inducing antibody-dependent cytotoxicity. Ivuxolimab can promote Tcell proliferation, survival and cytokine (such as IFN-γ, IL-2) secretion, inhibit regulatoryTcell function, and enhance anti-tumor immune response. Ivuxolimab can be used in the study of melanoma, hepatocellular carcinoma, head and neck squamous cell carcinoma, etc .
Vatelizumab (GBR500) is a monoclonal antibody that targets the α2 subunit (CD49b) of very late antigen 2 (VLA-2). Vatelizumab can be used for research on multiple sclerosis .
Efavaleukin alfa (AMG592) is a IL-2 mutein fragment crystallizable fusion protein. Efavaleukin alfa drives the selective expansion of regulatoryTcells. Efavaleukin alfa is applicable to research related to systemic lupus erythematosus .
Tagmokitug (CHS-114; SRF-114) is a fully human IgG1 antibody targeting CCR8. Tagmokitug selectively binds to human CCR8 (Kd = 502 pM) and mediates the death of CCR8-expressing cells via antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis. Tagmokitug selectively eliminates intratumoral regulatoryTcells, induces tumor growth inhibition, remodels the tumor immune microenvironment, and promotes the differentiation of cytotoxic CD8 +Tcell subsets. Tagmokitug can be used for the research of solid tumors .
MK-1966 is an anti-IL-10 antibody. MK-1966 inhibits secretion of cytokines from activated macrophages, production of CC and CXC chemokines, and a TH1 response, down-regulates MHC and costimulatory molecules on dendritic cells (DCs), and induces regulatoryTcells. MK-1966 can be used for the research of cancer , such as gastric cancer .
Anti-Mouse CTLA-4/CD152 (LALA-PG) Antibody (9D9) is a mouse-derived IgG2a κ type antibody inhibitor targeting to mouse CTLA-4/CD152. Anti-Mouse CTLA-4/CD152 (LALA-PG) Antibody (9D9) contains a LALA-PG mutation in the Fc fragment rendering it unable to bind to endogenous Fcγ receptors. Anti-Mouse CTLA-4/CD152 (LALA-PG) Antibody (9D9) can be used for the researches of cancer and immunology, such as colon .
Cergutuzumab is a fully human IgG1 antibody that targets carcinoembryonic antigen (CEA, CEACAM5, CD66e). Cergutuzumab can be used to form the recombinant protein Cergutuzumab amunaleukin (HY-P99498) .
GSK2618960 is a human monoclonal antibody (mAb) targeting IL-7Ra/CD127. GSK2618960 inhibits IL-7-induced STAT5 phosphorylation. GSK2618960 enhances CD4 T cell proliferation response and increases CD83, CD86, and CD209 expression in PBMCs. GSK2618960 can be used for the research of autoimmune and allergic inflammatory diseases. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
Ragifilimab (INCAGN-1876) is an agonist monoclonal antibody targeting the glucocorticoid-induced TNFR-related protein (GITR). Ragifilimab binds to and activates GITR on T cells, which stimulates the immune system to enhance its anti-tumor activity. Ragifilimab can be used for advanced or metastatic solid tumors research .
Quavonlimab (MK-1308) is a humanized IgG1 monoclonal antibody targeting CTLA-4. As a competitive inhibitor of CTLA-4, Quavonlimab blocks the binding of CTLA-4 to its ligands CD80 and CD86. Quavonlimab increases interferon production, expands and activates Tcells, reduces tumor regulatoryTcells, inhibits tumor growth, and induces the proliferation of Ki67-positive CD4 and CD8 cells. Quavonlimab can be used in studies related to solid tumors .
Tregalizumab is a humanized anti-human CD4 monoclonal antibody (IgG1 type) that selectively activates the suppressive properties of regulatoryTcells (Tregs) in vitro. Tregalizumab can be used in the research of autoimmune diseases (resulting from insufficient Treg activity) and allergies .
Revdofilimab (ABBV-368) is a human IgG1 agonist monoclonal antibody against OX40. Among them, OX40 is a member of the TNF receptor superfamily expressed on activated and memory Tcell subsets and Tregulatorycells .
BMS-986156 is a fully humanized IgG1 agonist monoclonal antibody agonist corticosteroid-induced tumor necrosis factor receptor-related protein (GITR). BMS-986156 binds to GITR and promotes activation of T effector cells and inactivates Tregulatorycells. BMS-986156 is indicated for use in advanced solid tumor studies .
Ieramilimab (LAG525; IMP701) is a humanized IgG4 monoclonal antibody that binds to LAG-3, resulting in inhibition of LAG-3 interaction with MHC-II molecules. Ieramilimab restores T-cell and NK-cell-mediated antileukemic immunity by reducing exhaustion and augmenting cytokine output and cytotoxicity. Ieramilimab increases the infiltration of cytotoxic T lymphocytes and reduces baseline densities of regulatoryTcells (Tregs) and ADAM10-expressing tumor cells. Ieramilimab can be used for the study of various malignancies including melanoma, RCC, and advanced solid tumors .
PTX-35 is a human IgG monoclonal antibody (mAb) targeting TNFRSF25. PTX-35 reduces the suppressive activity of regulatoryTcells and enhances CD4+ Tcell effector responses in a mouse melanoma model. PTX-35 can be used in Islet cell transplant rejection and Solid tumours research. Recommended isotype control: Human IgG1 lambda2, Isotype Control (HY-P990096) .
Anti-Mouse ICOS Antibody (7E.17G9) is a mouse ICOS agonist IgG2b monoclonal antibody. Anti-Mouse ICOS Antibody (7E.17G9) can upregulate ICOS expression and enhance Tcell function. Anti-Mouse ICOS Antibody (7E.17G9) can significantly inhibit the immune regulatory function of dendritic cells (DCs). Anti-Mouse ICOS Antibody (7E.17G9) can eliminate transplant tolerance. Anti-Mouse ICOS Antibody (7E.17G9) can be used for researches on inflammation conditions, cancer and xenotransplantation such as nephritis and pancreatic cancer .
Imneskibart (AU-007) is a human monoclonal antibody that binds to the CD25-binding epitope of interleukin-2 (IL-2), blocking the binding of IL-2 to the trimeric IL-2 receptor while retaining the ability to bind to the dimeric IL-2 receptor. Imneskibart expands effector Tcell and NK cell populations, reduces regulatoryTcells, increases the effector Tcell/regulatoryTcell ratio, and alleviates vascular leakage. Imneskibart can be used in research related to melanoma and non-small cell lung cancer. The corresponding isotype control is: Human IgG1 kappa, Isotype Control (HY-P99001) .
Porustobart (HBM-4003) is a fully human anti-CTLA-4 heavy chain only antibody (HCAb). Porustobart can significantly improve the depletion of regulatoryTcells (Treg cells) with high CTLA-4 expression in tumor tissues by enhancing ADCC activity. Porustobart can be used for tumor research .
Efizonerimod alfa (MEDI-6383) is a recombinant human OX40L IgG4P Fc fusion protein that assembles into a hexameric structure and exerts potent agonist activity upon binding to OX40. The activity of Efizonerimod alfa is enhanced by Fcγ receptor-mediated aggregation. Efizonerimod alfa binds to OX40 on the surface of activated Tcells, induces NF-κB promoter activity in OX40-expressing Tcells, and triggers the production of Th1-type cytokines, Tcell proliferation, and resistance to regulatoryTcell (Treg)-mediated suppression. Efizonerimod alfa enhances the cytolytic activity of tumor-reactive Tcells and slows tumor growth in immunodeficient mice. Efizonerimod alfa induces the proliferation of CD4, CD8, and B cells in the peripheral blood of healthy non-human primates. Efizonerimod alfa can be used in the research of advanced solid malignancies and melanoma .
Anti-Mouse/Human KLRG-1 Antibody (2F1) is a Syrian hamster-derived IgG type antibody inhibitor, targeting to mouse/human KLRG-1. Anti-Mouse/Human KLRG-1 Antibody (2F1) neutralizes KLRG1. Anti-Mouse/Human KLRG-1 Antibody (2F1) reduces T-cell receptor signals and regulatoryT-cell accumulation. Anti-Mouse/Human KLRG-1 Antibody (2F1) can be used for the researches of immunology .
ASP-1948 is a human monoclonal antibody (mAb) targeting NRP1/VEGF165R/CD34. ASP-1948 reverses the suppressive effects of regulatoryTcells. ASP-1948 can be used in solid tumors research .
FB102 is an anti-human CD122 (IL-2Rβ) monoclonal antibody with selective activity. FB102 blocks the proliferation and activation of pathogenic NKcells and specific Tcell subsets induced by IL-2 and IL-15, without affecting the proliferation of regulatoryTcells. FB102 inhibits IL-2/IL-15-induced activation of CD4+ and CD8+ Tcells in in vitro disease models. FB102 is applicable to research related to celiac disease .
GIGA-564 is a fully human anti-CTLA4 IgG1 monoclonal antibody with a Kd of 9.8 nM. GIGA-564 binds to a unique epitope of CTLA-4, mediates FcR-dependent signaling pathways, depletes CTLA-4-highly-expressing regulatoryTcells within tumors, and inhibits the proliferation of peripheral regulatoryTcells. GIGA-564 exhibits anti-tumor activity in mouse models. GIGA-564 can be used for tumor research .
DS-1055a is an anti-human GARP antibody. DS-1055a effectively depletes GARP-positive regulatoryTcells in the tumor microenvironment, and activates effector Tcells. DS-1055a exhibits antitumor activity and can be used for the research of cancer, such as colon cancer .
SHR-1806 is a OX40 agonist and a NF-κB activator, with antitumor activity. SHR-1806 mediates ADCC and CDC effects, enhances the function and expansion of effector Tcells, suppresses regulatoryTcells, and increases γ-interferon secretion. SHR-1806 exhibits typical pharmacokinetic characteristics and favorable safety profiles. SHR-1806 can be used in studies related to solid tumors and colon cancer .
REGN6569 is a fully human IgG1 monoclonal antibody targeting glucocorticoid-induced tumor necrosis factor receptor-related protein (GITR) with high specificity for GITR. REGN6569 exerts stronger in vitro antibody-dependent cell-mediated cytotoxicity (ADCC) against regulatoryTcells expressing GITR. REGN6569 selectively depletes regulatoryTcells via antibody-dependent cell-mediated cytotoxicity and increases the proportion of proliferative natural killer (NK) cells in peripheral blood. REGN6569 is applicable for advanced solid malignancies. Isotype control: HY-P99001 .
JNJ-64164711 (JNJ-711) is a bifunctional antibody that simultaneously targets human GITR/TNFRSF18 and FcγRIIIa. JNJ-64164711 binds to the GITR domain to activate the NF-κB signaling pathway, while binding to FcγRIIIa to support antibody-dependent cellular cytotoxicity (ADCC). JNJ-64164711 can specifically eliminate GITR-positive hematological tumor cells, activated Tcells and intratumoral regulatoryTcells through the ADCC mechanism, thereby significantly enhancing the body's anti-tumor immune response. JNJ-64164711 can be used in research related to non-small cell lung cancer, colorectal cancer, prostate cancer, renal cell carcinoma and hematological tumors .
HB0030 is a TIGIT inhibitor with antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) activities. HB0030 enhances the expression of activation markers in natural killer (NK) cells, promotes the killing of regulatoryTcells (Tregs), and reduces the proportion of FoxP3 +Treg in tumor-infiltrating lymphocytes. The combination of HB0030 with the anti-PD-L1/VEGF bispecific antibody HB0025 further enhances tumor suppression efficacy. HB0030 can be used in studies related to colorectal cancer, pancreatic adenocarcinoma, hepatocellular carcinoma, bladder cancer, breast cancer, non-small cell lung cancer, and advanced solid tumors .
Anti-ZnT8 Antibody (mAb43) is a monoclonal antibody targeting the zinc transporter ZnT8, with islet-specific biodistribution characteristics. Anti-ZnT8 Antibody (mAb43) binds to extracellular ZnT8 on the surface of pancreatic β-cells and masks its insulin-co-localizing sites to block autoimmune recognition. Anti-ZnT8 Antibody (mAb43) also promotes an increase in the proportion of regulatoryTcells and inhibits B cell antigen presentation, thereby effectively blocking the Tcell-mediated cascade of β-cell destruction. Anti-ZnT8 Antibody (mAb43) eliminates insulitis, preserves β-cell mass and induces seroconversion of autoantibodies, without directly altering the insulin secretion function or content of β-cells. Anti-ZnT8 Antibody (mAb43) can be used for research related to type 1 diabetes .
HLX51 is a regulatoryTcell inhibitor and OX40/CD134/TNFRSF4 agonist with tumour growth inhibitory activity. HLX51 inhibits regulatoryTcell differentiation and activity, relieves tumour microenvironment immunosuppression, enhances effector Tcell function. HLX51 competitively binds OX40, activates OX40, promotes immune cell proliferation and Tcell killing ability. HLX51 modulates immune cell function to inhibit tumour growth. HLX51 can be used for the research of advanced/metastatic solid tumours and lymphomas .
OX118 is a fully human, ADCC-enhanced monoclonal antibody targeting OX40L, the recommended isotype control is HY-P99001. OX118 blocks OX40L, suppresses effector T-cell proliferation, expands regulatoryT-cell populations, and reduces bystander activation across natural killer cells, B cells, and CD14+ monocytes. OX118 can be used for the research of graft-versus-host disease .
YH004 is an anti-CD137 agonistic monoclonal antibody, with immunostimulating and antineoplastic activities. YH004 activates CD137 expressed on a variety of leukocyte subsets including activated T lymphocytes and natural killer cells. YH004 enhances CD137-mediated signaling and induces cytotoxic T-lymphocyte (CTL) proliferation, cytokine production and promotes anti-tumor response mediated by CTL. YH004 induces NK-mediated tumor cell killing and suppresses the immunosuppressive activity of regulatoryTcells. YH004 can be studied in anticancer research .
Anti-Mouse CD4 Antibody (YTS 177) reacts with the mouse CD4. Anti-Mouse CD4 Antibody (YTS 177) shows non-depleting but binding does induce rapid internalization of CD4 on both CD4 + Foxp3- Tcells and Foxp3 +regulatoryTcells. Recommend Isotype Controls: Rat IgG2a kappa, Isotype Control (HY-P990679) .
RTX-003 is a monoclonal antibody targeting CD25. RTX-003 induces the death of regulatoryTcells (Tregs) by targeting the IL-2 receptor α chain (CD25), and can enhance anti-tumor immune responses.
DS-1055a (FUT8-KO) is an anti-human GARP antibody that has knocked out the fucosyltransferase 8 gene (FUT8). It exhibits enhanced antibody-mediated cytotoxicity (ADCC) effect. DS-1055a (FUT8-KO) can effectively eliminate GARP-positive regulatoryTcells in the tumor microenvironment and activate effector Tcells. DS-1055a (FUT8-KO) has anti-tumor activity and can be used in cancer research (such as colon cancer) .
PLT012 is a humanized IgG4 antibody targeting CD36. PLT012 inhibits the lipid-binding domain of CD36. PLT012 blocks CD36-mediated metabolic adaptation in regulatoryTcells (Tregs) and CD8 + tumor-infiltrating lymphocytes (TILs), thereby inhibiting tumor growth and shifting the tumor microenvironment from immunosuppressive to immunosupportive. PLT012 reduces intratumoral Tregs, enhances CD8 +Tcell infiltration and cytotoxic function, and increases the abundance of progenitor-exhausted Tcells. PLT012 exerts robust antitumor activity and synergizes with anti-PD-L1 or standard-of-care regimens (anti-VEGF + anti-PD-L1). PLT012 can be used for hepatocellular carcinoma, colorectal cancer and solid tumor research .
HFB200901 is a galectin LGALS9 inhibitor and immunostimulant that can be used in studies related to pancreatic adenocarcinoma, pancreatic intraepithelial neoplasia, KRAS G12C-mutant colon cancer, and prostate cancer. HFB200901 disrupts the LGALS9/TIM-3 axis, while blocking the internalization and vacuolization of recombinant LGALS9. HFB200901 reduces the proportion of regulatoryTcells (Treg) and enhances dendritic cell activation, thereby inducing polyfunctional and memory CD8 +Tcell responses. HFB200901 inhibits the progression of pancreatic neoplastic lesions and effectively improves the efficacy of PSMA-based vaccination .
Anti-Human/Mouse LY6E Antibody (9B12) is a high-affinity, multi-target antibody that binds specifically to LY6E. Anti-Human/Mouse LY6E Antibody (9B12) binds specifically to cell-surface LY6E and enters lysosomes via lipid raft-dependent endocytosis, thereby effectively inhibiting the growth of various LY6E-expressing solid tumors (such as breast cancer and lung cancer) in both in vitro and in vivo models. Anti-Human/Mouse LY6E Antibody (9B12) exerts a dual mechanism of action: on one hand, it blocks the interaction between PILRα and CD8α, specifically reduces the survival rate of peripheral CD8 +Tcells and induces their activation, breaking the state of cellular quiescence; on the other hand, it recognizes and immunoprecipitates IDE under both non-denaturing and denaturing conditions, which is applicable to studies on the subcellular localization and protein interactions of IDE. The regulatory effect of Anti-Human/Mouse LY6E Antibody (9B12) on CD8 +Tcells strictly depends on the presence of PILRα, and it does not affect CD4 +Tcells or Tcell development in the thymus, exhibiting high specificity .
ZL-1218 is a selective humanized IgG1 antibody, targeting CCR8. ZL-1218 induces antibody-dependent cellular cytotoxicity (ADCC), leading to NK cell-mediated depletion of CCR8-expressing regulatoryTcells (Tregs). ZL-1218 blocks the binding of the CCR8 ligand CCL1 to CCR8 and reduces Treg recruitment by inhibiting the chemotaxis of CCR8 +cells. ZL-1218 reduces intratumoral Treg levels in a dose-dependent manner. ZL-1218 exerts enhanced antitumor activity when combined with the anti-PD-1 antibody. ZL-1218 can be used for solid tumour research .
TNX-1500 is a crystallizable fragment-modified anti-CD154 antibody. TNX-1500 contains the hu5c8 fragment antigen-binding (Fab) domain from Ruplizumab (HY-P99315) and an IgG4 Fc region engineered to reduce FcγRIIa binding. TNX-1500 has significantly weaker binding affinity to FcγRI, FcγRIIaH, FcγRIIbF, FcγRIIIaF, and FcγRIIIaV compared to hu5c8 (Kdvalues: 8.7 nM, 7100 nM, 4900 nM, 8000 nM, 6000 nM respectively). TNX-1500 prolongs nonhuman primate renal allograft survival, prolongs nonhuman primate cardiac allograft survival. TNX-1500 can be used for the research of allograft rejection [1][2].
Lactose is a β-galactoside consisting of galactose and glucose residues, the main carbohydrate in mammalian breast milk. Lactose, a macronutrient and an inducer of host innate immune responses, possesses immune modulatory functions .
(-)-Camphoric acid is the less active enantiomer of Camphoric acid. Camphoric acid induces glutamate receptor expression. Camphoric acid also significantly induces the activation of NF-κB and AP-1. Camphoric acid significantly stimulates the differentiation of mouse osteoblastic MC3T3-E1 subclone 4 cells. Camphoric acid has weak regulatory function towards glutamate receptors. Camphoric acid can induce mRNA expression of glutamate signaling molecules and activate transcription factors, thereby stimulating osteoblast differentiation .
PSMα3 is an inhibitor of NF-κB p65 and p38 MAPK. PSMα3 forms membrane pores and binds to residues of human insulin B chain to inhibit insulin aggregation. PSMα3 forms α-type amyloid-like fibrils to exert cytotoxic effects, and acts as a functional amyloid virulence determinant of Staphylococcus aureus. PSMα3 is applicable to research related to spondyloarthritis, rheumatoid arthritis, insulin-derived amyloidosis, and Staphylococcus aureus infection .
4A-MPLA ammonium is an orally active TLR4 agonist. 4A-MPLA ammonium induces TLR4 endocytosis dependent on Cdc42 and galectin-3, triggering TRIF-mediated signaling and sustained IFN-β production. 4A-MPLA ammonium promotes lipid droplet formation, upregulates interferon-stimulated genes and type I IFN signaling genes, downregulates lysosome/phagosome function genes, and modulates tolerogenic dendritic cell function. 4A-MPLA ammonium can be used for the research of colitis .
Resolvin D5 is an anti-inflammatory and analgesic agent produced in M2 macrophages. Resolvin D5 alleviates Paclitaxel (HY-B0015)-induced mechanical allodynia and inflammatory pain by activating the GPR32 receptor, with gender specificity (effective only in male mice) and independence from TRPV1 or TRPA1 channels. Resolvin D5 attenuates LPS-induced ERK phosphorylation and NF-κB nuclear translocation, downregulates proinflammatory mediators such as IL-6 and CCL5, inhibits Th17 cell differentiation and osteoclastogenesis, promotes regulatoryTcell differentiation, and shows no cytotoxicity to human monocytes. The level of Resolvin D5 is elevated in arthritic SKG mice, but Resolvin D5 has no effect on dendritic cell differentiation or M1 macrophage polarization, nor does it prevent ZyA-induced arthritis progression. Resolvin D5 is suitable for research related to chemotherapy-induced peripheral neuropathy, inflammatory pain and rheumatoid arthritis .
The CRTAM/CD355 protein is a key mediator of heterophilic intercellular adhesion and complexly regulates the activation, differentiation, and tissue retention of T cell subsets. Its interaction with CADM1 promotes NK cell cytotoxicity and CD8+ T cell secretion of IFNG, thus contributing to NK cell-mediated tumor rejection. CRTAM/CD355 Protein, Human (HEK293, His) is the recombinant human-derived CRTAM/CD355 protein, expressed by HEK293 , with C-6*His labeled tag.
The CRTAM/CD355 protein is a key mediator of heterophilic intercellular adhesion and complexly regulates the activation, differentiation, and tissue retention of T cell subsets. Its interaction with CADM1 promotes NK cell cytotoxicity and CD8+ T cell secretion of IFNG, thus contributing to NK cell-mediated tumor rejection. CRTAM/CD355 Protein, Human (Biotinylated, HEK293, His) is the recombinant human-derived CRTAM/CD355 protein, expressed by HEK293, with C-His labeled tag.
CRTAM/CD355 Protein is an immunoglobulin-superfamily transmembrane protein, and is a member of nectin-like protein superfamily. CRTAM is also expressed on activated human NK cells, CD8+ T cells and a subset of CD4+ T cells. CRTAM takes part in cellular adhesion, polarity, and proliferation. CRTAM also regulates lymphocyte function, and promotes TCD8+ cell adhesion and retention within the lymph node. Furthermore, CRTAM can interact with Necl-2, and promotes cytotoxicity of NK cells and IFN-γ secretion of CD8+ T cells in vitro, and NK cell-mediated rejection of tumors expressing Necl-2 in vivosup>[3]. CRTAM/CD355 Protein, Cynomolgus (HEK293, His) is the recombinant cynomolgus-derived CRTAM/CD355 protein, expressed by HEK293 , with C-6*His labeled tag.
Isoallolithocholic acid-d2 is the deuterium labeled Isoallolithocholic acid (HY-B0172A). Isoallolithocholic acid is a Tcellregulator and enhances regulatoryTcells (Tregs) differentiation .
1,10-Decanediol-d20 is the deuterium labeled 1,10-Decanediol . 1,10-Decanediol is a diol compound that can react with α-ketoglutarate (aKG) to generate polymeric microparticles (termed paKG MPs) for the sustained release of aKG, thereby promoting immunosuppressive regulation. Additionally, paKG MPs can bind to dendritic cells (DCs), reducing their glycolysis and mitochondrial respiration in vitro. These metabolic changes lead to the modulation of MHC-II and CD86 expression in DCs and alter the frequency of regulatoryTcells (Tregs) as well as T-helper type 1/2/17 cells in vitro. 1,10-Decanediol can be used in research within the field of immunometabolism. can be used as a surfactant/stabilizer in the synthesis of nanomaterials .
SS47 TFA, a PROTAC-based HPK1 degrader, exerts proteasome-mediated HPK1 degradation. The degradation of HPK1 via SS47 also significantly enhances the in vivo antitumor efficacy of BCMA CAR-Tcell research. HPK1, an immunosuppressive regulatory kinase, is a promising target for cancer immunotherapies . SS47 (TFA) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
ODN 1018 (1018 ISS) is a TLR9 agonist and immune modulator. ODN 1018 exhibits adjuvant activity and augments CD8+ T cell responses with LNP-encapsulated OVA peptides. ODN 1018 triggers sustained suppression of allergic airway inflammation. ODN 1018 can be used for the research of allergic asthma and systemic lupus erythematosus .
ODN 2216 is a type A CpG oligodeoxynucleotide vaccine adjuvant and a TLR9 agonist. ODN 2216 interacts with TLR9 in the lysosomes of CD4 +Tcells and activates feedback-dependent signaling pathways. ODN 2216 induces the production of type I interferons, IL-6 and TGF-β via the IRAK4/IRF7 axis, while increasing intracellular ATP levels. ODN 2216 not only induces the differentiation of CD4 +Tcells into anti-inflammatory Th3-like regulatory phenotypes to inhibit autologous proliferation, but also enhances the specific CD8 +Tcell-mediated cytotoxicity against Mammaglobin-A in breast cancer cells. ODN 2216 is widely used in studies related to breast cancer and systemic lupus erythematosus .
ODN 2216 sodium is a type A CpG oligodeoxynucleotide vaccine adjuvant and a TLR9 agonist. ODN 2216 sodium interacts with TLR9 in the lysosomes of CD4 +Tcells and activates feedback-dependent signaling pathways. ODN 2216 sodium induces the production of type I interferons, IL-6 and TGF-β via the IRAK4/IRF7 axis, while increasing intracellular ATP levels. ODN 2216 sodium not only induces the differentiation of CD4 +Tcells into anti-inflammatory Th3-like regulatory phenotypes to inhibit autologous proliferation, but also enhances the specific CD8 +Tcell-mediated cytotoxicity against Mammaglobin-A in breast cancer cells. ODN 2216 sodium is widely used in studies related to breast cancer and systemic lupus erythematosus .
ODN 1668, a class B CpG ODN (oligodeoxynucleotide), is a TLR-9 agonist. ODN 1668 has strong immune regulatory properties, can enhance the level of antibody IgG2 subtype, promote the immune response of Tcells and B cells, and can be used in the study of vaccine adjuvants. In addition, CpG ODN 1668 induces an antimicrobial immune response via a CaTLR9 dependent pathway in groupers. Sequence: 5'-tccatgacgttcctgatgct-3’ .
ODN 1668 sodium, a class B CpG ODN (oligodeoxynucleotide), is a TLR-9 agonist. ODN 1668 sodium has strong immune regulatory properties, can enhance the level of antibody IgG2 subtype, promote the immune response of Tcells and B cells, and can be used in the study of vaccine adjuvants. In addition, CpG ODN 1668 sodium induces an antimicrobial immune response via a CaTLR9 dependent pathway in groupers. Sequence: 5'-tccatgacgttcctgatgct-3’ .
AZD8701 (IONIS-1063734) is an antisense oligonucleotide targeting FOXP3 in regulatoryTcells (Tregs), with a human IC50 of 65.2 nM. AZD8701 binds to intronic sites of all FOXP3 pre-mRNA isoforms and mediates dose-dependent FOXP3 knockdown via free uptake. AZD8701 can be used in cancer-related research .
AZD8701 (IONIS-1063734) sodium is an antisense oligonucleotide targeting FOXP3 in regulatoryTcells (Tregs). AZD8701 sodium can relieve immunosuppression in cancer .
Human IL2RA mRNA encodes the human interleukin 2 receptor subunit alpha (IL2RA) protein, a receptor for interleukin-2. IL2RA is involved in the regulation of immune tolerance by controlling regulatoryTcells (TREGs) activity.
AS2863619 GMP is AS2863619 (HY-126675) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. AS2863619 is an orally active CDK8/19 inhibitor that also inhibits BMP2, MDA5 and RIG-I receptors. AS2863619 targets Stat5a-CDK8/19 to promote the differentiation of CD4 +Tcells into regulatoryTcells and induce FOXP3 expression, thereby restoring immune homeostasis and establishing transplant immune tolerance. AS2863619 also enhances the BMP2/SMAD signaling pathway to promote osteogenic differentiation and inhibit adipogenic differentiation. AS2863619 exerts osteoprotective effects by alleviating inflammation-induced impairment of osteogenic function and inducing neutrophil apoptosis (apoptosis). AS2863619 can be applied to research in related fields such as periodontitis-induced bone defects .
Inquiry Online
Your information is safe with us. * Required Fields.
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
MedchemExpress Validation 03
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
MedchemExpress Validation 04
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedchemExpress Validation
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedchemExpress Validation
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedchemExpress Validation
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedchemExpress Validation
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedchemExpress Validation
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedchemExpress Validation
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedchemExpress Validation
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedChemExpress values your privacy and your trust is important to us. We use cookies to enhance your website experience. Some cookies are necessary to run the website.
Privacy and Cookie Policy
